"We're not doing 30 bets a year": Vijay Pande on betting small after running $4 billion at a16z | TechCrunch

Vijay Pande, the former leader of Andreessen Horowitz's healthcare and life sciences division, has stepped away from managing a multi-billion dollar portfolio to co-found VZVC, a boutique venture capital firm focused on highly selective, concentrated investments.

Rather than pursuing the high-volume approach typical of major investment firms that back dozens of startups annually, Pande and his partner aim to invest in only about five carefully chosen companies each year. This new enterprise is intentionally designed to remain exceptionally lean, featuring just two primary partners who utilize artificial intelligence agents to automate daily operations, effectively eliminating the traditional need for junior associates.

In discussing the venture's focus, Pande highlights the massive evolution in biotechnology, where artificial intelligence increasingly helps engineer novel drugs, target specific diseases, and streamline expensive clinical trials. However, he cautions that the sector faces unique challenges, particularly because biological datasets cannot simply be scraped from the web like text, requiring companies to generate their own proprietary databases. Ultimately, VZVC intends to leverage Pande's deep expertise to support long-term, high-integrity founders who understand that commercializing scientific breakthroughs requires applying just as much creativity to their go-to-market strategies as they do to their underlying technology.